December 1, 2004

1 min read

Antidepressants: Good Drugs or Good Marketing?

A scandal over hidden data about adolescent suicide lights a dark corner of our drug approval system

By David Dobbs

00

(Further Reading)

  • Suppression of Mosholder’s findings and testimony is documented by Anna Wilde Mathews’s article “In Debate over Antidepressants, FDA Weighed Risk of False Alarm Doubting Data on Suicide and Kids” in Wall Street Journal; May 25, 2004. Viewable at www.ahrp.org/infomail/04/05/25.html

  • Drug Company Experts Advised Staff to Withhold Data about SSRI Use in Children. Wayne Kondro in Canadian Medical Association Journal, Vol. 170; No. 5; March 2, 2004. Available online at www.cmaj.ca/cgi/content/full/170/5/783

More by David Dobbs
SA Mind Vol 14 Issue 5This article was originally published with the title “Perspectives: Antidepressants: Good Drugs or Good Marketing” in SA Mind Vol. 14 No. 5 (), p. 10
doi:10.1038/scientificamericanmind1204-10
View This Issue